KISS1 and type 2 diabetes mellitus: IVGTT‐DI quantifies the ability of the β‐cell to counter insulin resistance,32 with lower baseline IVGTT‐DI values independently predicting conversion from normal glucose tolerance or impaired glucose tolerance to type 2 diabetes within 5 years.32 Therefore, our finding that kisspeptin increases GSIS and IVGTT‐DI shows metabolically the beneficial effects of kisspeptin.